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Abstract
Coherence between the bioelectric activity of sensorimotor cortex and contralateral muscles can be observed around 20 Hz.
By contrast, physiological tremor has a dominant frequency around 10 Hz. Although tremor has multiple sources, it is partly
central in origin, reflecting a component of motoneuron discharge at this frequency. The motoneuron response to ,20 Hz
descending input could be altered by non-linear interactions with ,10 Hz motoneuron firing. We investigated this further
in eight healthy human subjects by testing the effects of the beta-adrenergic agents propranolol (non-selective b-
antagonist) and salbutamol (b2-agonist), which are known to alter the size of physiological tremor. Corticomuscular
coherence was assessed during an auxotonic precision grip task; tremor was quantified using accelerometry during index
finger extension. Experiments with propranolol used a double-blind, placebo-controlled crossover design. A single oral dose
of propranolol (40 mg) significantly increased beta band (15.3–32.2 Hz) corticomuscular coherence compared with placebo,
but reduced tremor in the 6.2–11.9 Hz range. Salbutamol (2.5 mg) was administered by inhalation. Whilst salbutamol
significantly increased tremor amplitude as expected, it did not change corticomuscular coherence. The opposite direction
of the effects of propranolol on corticomuscular coherence and tremor, and the fact that salbutamol enhances tremor but
does not affect coherence, implies that the magnitude of corticomuscular coherence is little influenced by non-linear
interactions with 10 Hz oscillations in motoneurons or the periphery. Instead, we suggest that propranolol and salbutamol
may affect both tremor and corticomuscular coherence partly via a central site of action.
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Introduction
Many studies have investigated oscillatory coupling between the
sensorimotor cortex and the periphery using coherence analysis.
During steady contractions, cortical recordings (electroencephalo-
gram, EEG, or magnetoencephalography, MEG, in humans, local
field potentials in animals) show coherence with contralateral
rectified electromyogram (EMG) at frequencies of 15–30 Hz [1–
6]. Both efferent and afferent (feedback) pathways contribute to
this oscillatory coupling [7–11].
In the periphery, oscillations are greatest at ,10 Hz. Physio-
logical tremor has a strong component around this frequency,
probably as a result of multiple interacting factors. These include
mechanical resonance at skeletal articulations [12], the stretch
reflex loop [13], motor unit recruitment [14] and motor unit
synchronisation [15]. A component of ,10 Hz physiological
tremor is centrally generated [15–17]. Although both cortical and
muscle recordings show oscillations around 10 Hz and 20 Hz,
significant corticomuscular coherence is usually only seen for the
higher frequency band, despite ,10 Hz oscillations being
effectively carried from the motor cortex down the corticospinal
tract [18]. We have recently provided evidence that neural circuits
in the spinal cord phase invert signals around 10 Hz [19,20].
Convergence of in-phase and out-of-phase signals on motoneurons
results in phase cancellation, reducing the amplitude of signals at
frequencies related to physiological tremor. This may have
functional consequences in improving movement precision.
The non-linear nature of spinal circuits means that interactions
can occur across different frequency bands. For example, our
previous computational modelling suggested that recurrent inhi-
bition by Renshaw cells will boost signals around 30 Hz, at the
same time as reducing those around 10 Hz, leading to a reciprocal
modulation of power at these frequencies [19]. Conversely, the
highly periodic nature of motoneuron firing at low forces can
produce oscillations in motor output, even when the synaptic input
to motoneurons is not oscillatory [19]. As the firing of the
motoneuron pool becomes more or less periodic, this effect will
mean that the amplitude of oscillations at 10 Hz and 20 Hz tends
to co-modulate. We were interested to examine experimentally
how motor systems oscillations at different frequencies might
interact, since this could tease apart the different factors
influencing oscillatory amplitude and coupling.
One approach to this issue is to manipulate the system
pharmacologically. We have previously shown that the benzodi-
azepine diazepam modulates cortical oscillations in the beta band,
without altering coupling to the periphery [21]. By contrast, the
anti-epileptic drug carbamazepine increases beta band cortico-
muscular coherence, without affecting the amplitude of cortical
oscillations [22]. However, neither of these agents affected
oscillations around 10 Hz. Clinically, the most powerful effects
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on physiological tremor are produced by beta-adrenergic agents.
The beta-adrenergic agonists enhance tremor (adrenaline [23];
isoprenaline [24]; salbutamol [25]), whereas the antagonist
propranolol reduces it [24]. These drugs are generally believed
to act by changing the gain of muscle receptors and spinal reflex
loops, mediated via peripherally located b2-adrenergic receptors
[23,24,26–28]. If the effects of beta-adrenergic agents are solely
peripheral, they will change the gain of peripheral feedback, which
would inject oscillations into motoneuron firing. This might co-
modulate oscillations at 10 Hz and 20 Hz [19].
In this paper, we test this idea directly. Surprisingly, we show
that propranolol increases ,20 Hz corticomuscular coherence but
reduces tremor at ,10 Hz, and that salbutamol has no significant
effect on ,20 Hz corticomuscular coherence, but markedly
increases ,10 Hz tremor. These opposite effects on oscillations
at 10 Hz and higher frequencies are similar to those seen in a
computational model of recurrent feedback by Renshaw cells [29],
and are not expected if these agents only act peripherally. We
speculate that beta-adrenergic agents also have a central action,
allowing opposite effects on physiological tremor and beta-band
corticomuscular coherence.
Methods
Experiments were performed on 8 young healthy right-handed
volunteer subjects (3 female; age range 21–32 years) without a
family history of essential tremor. None of the subjects were taking
prescription medication either regularly or as required. Subjects
were not pre-selected based on their corticomuscular coherence.
None of the subjects had received a prior diagnosis of enhanced
physiological tremor or had evidence of enhanced physiological
tremor when assessed by a clinical neurologist (MRB) at the time
of experiments.
Ethics statement
Informed written consent was obtained in accordance with the
Declaration of Helsinki and all procedures were approved by the
Cambridge Local Research Ethics Committee.
Electrophysiological Recordings
Surface EMGs from the right upper limb were recorded with
adhesive electrodes (Biotrace 0713C, MSB, Marlborough, UK).
Recordings were made from first dorsal interosseous (1DI),
abductor pollicis brevis (AbPB), abductor digiti minimi (AbDM),
flexor digitorum superficialis (FDS), and extensor digitorum
communis (EDC), with an inter-electrode distance of 1.5–2 cm.
Differential EEG was recorded from the left sensorimotor cortex
using two adhesive scalp electrodes (Neuroline 720 00-S,
Medicotest, St Ives, UK) placed 30 mm lateral to the vertex and
20 mm anterior and posterior to the interaural line. The anterior
EEG electrode was connected to the non-inverting input of the
amplifier; this is the same montage as used in our previous work
[7,11,21,22,30]. Signals were amplified (EMG gain 500–5000;
EEG gain 50 k) and bandpass filtered (EMG 30 Hz-2 kHz; EEG
3 Hz-2 kHz) before being digitised at 4273.5 Hz by a Power1401
interface (Cambridge Electronic Design Ltd, Cambridge, UK)
connected to a computer running Spike2 software (Cambridge
Electronic Design Ltd).
Measurement of Tremor
Physiological tremor was quantified using accelerometry. A low
mass splint was taped to the subject’s right index finger, and
restricted movements to the metacarpophalangeal joint. Subjects
gripped a fixed vertical pole with the thumb and digits 3–5, and
extended the index finger. A miniature accelerometer (Isotron
25B, Endevco, San Juan Capistrano, CA, USA) was fixed to the
end of the splint, with its sensitive axis aligned to detect finger
flexion/extension movements. Recordings were made for 90 s.
Precision Grip Task
Measurement of corticomuscular coherence was carried out
using an auxotonic precision grip task. Subjects held the two levers
of a purpose-built manipulandum between thumb and index
finger. The aluminium levers (2068061.5 mm) were attached to
the shafts of two computer-controlled torque motors, which
incorporated optical encoders for position measurement. At rest
the levers were separated by 70 mm; a 1 N force was required to
move the levers off their end-stops.
The task (see Figure 1) required subjects to maintain cursors
representing each lever position within two moving target boxes
on a computer screen. Movement of the levers was resisted by the
torque motors, which simulated an auxotonic (spring-like) load.
The target boxes produced a hold-ramp-hold pattern, with the
first hold requiring a rapid lever displacement of 12 mm from rest
followed by a hold period of 3 s at a force level of 1.3 N. The
targets then produced a 2 s ramp movement to reach the second
hold, with a displacement of 24 mm, 1.6 N force and duration of
3 s, before subjects released the levers. This is the COMP1 task of
Kilner et al. [6], and has been used in several of our previous
publications [7,11,21,22,30].
Experimental Protocol and Drug Administration
Drugs were prescribed and administered by one of the authors
(MRB), who is a clinical neurologist. Potential adverse reactions
were minimised by using the lowest therapeutic dose recom-
mended by the Joint Formulary Committee [31].
Propranolol experiments were conducted as a double blind
randomised placebo-controlled trial. For each subject, placebo and
propranolol (40 mg of active compound mixed with vehicle
compound), which were indistinguishable in appearance, were
randomly assigned a label A or B by an independent randomizer.
Each subject participated in experiments on two days, separated
by a 2–3 week washout period. At the start of the morning session
of each day, the subject was prepared for recording. A control
experiment was then carried out, which consisted of 80 trials of the
precision grip task and a measurement of tremor. After this, the
electrode locations were marked on the skin with ink and the
subject ingested experimental compound A (first day) or B (second
day). Four hours later, when peak serum concentrations of the
active agent should have been achieved [32], the subject returned
to the laboratory. Fresh adhesive electrodes were applied at the
marked muscle and scalp locations, and further recordings were
made. The identities of compound A and B for each subject were
only revealed by the randomizer once all experiments were
complete and data were ready for analysis. By using a placebo, we
were able to control for effects caused by the different time of day
of the experimental and control recording sessions, which we have
previously shown to be important [22].
The subjects who had participated in the propranolol experi-
ments were also used in the salbutamol experiments, following a
washout period of at least one week. After the control recordings,
2.5 mg of salbutamol was inhaled by the subject as an aerosolised
solution produced by a nebuliser. Inhaled aerosolised salbutamol is
absorbed rapidly via the lungs into the bloodstream. Maximum
serum concentrations are achieved ,10 minutes after inhalation
[33]. Nebulised salbutamol, at a dose of 40 mg/kg, results in an
average serum concentration of 2.5 ng/ml after inhalation [34].
The rapid absorption meant that control and test experiments
Beta-Adrenergic Effects on EEG-EMG Coherence
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were separated by only a short period, and we accordingly
considered it unnecessary to carry out placebo experiments for
salbutamol (see paragraph 12 of the Results section for further
justification).
Electrocardiogram (ECG) was monitored throughout the
salbutamol experiments. Salbutamol at an average plasma
concentration of 2.5 ng/ml produces a 10% increase in heart
rate above baseline [34]. The second recording session (after
salbutamol) was therefore only commenced after the heart rate
had increased by 10% relative to baseline.
Analysis
All data analysis was performed using custom written MATLAB
(Mathworks Inc.) routines, and followed the procedures used in
our prior publications [7,22]. Prior to analysis EMG recordings
were full wave rectified.
Analysis of tremor power used 0.88 s long (4096 points for a
sampling rate of 4630 Hz) sequential non-overlapping data
sections, taken from the entire available duration of the
accelerometer recording. These were processed with a Fast
Fourier Transform, yielding a tremor power spectrum with
frequency resolution of 1.13 Hz.
Analysis for the precision grip task focused upon the second
hold phase, when ,20 Hz corticomuscular coherence is greatest
[6]. EEG and EMG power spectra, and coherence between EEG
and EMG, were computed using three contiguous 0.88 s-long
sections of data taken from this task phase of each trial, and a
4096-point-long Fast Fourier Transform [3].
Figure 1. Experimental tasks. A. Postural tremor task. B. Example of postural physiological tremor in a single subject, recorded via an
accelerometer. C. Auxotonic precision grip task. D. Lever displacement and average rectified EMG recorded from extensor digitorum communis (EDC),
flexor digitorum supeficialis (FDS), abductor digiti minimi (AbDM), abductor pollicis brevis (AbPB) and first dorsal interosseous (1DI) muscles in a single
subject during a single trial of the auxotonic task.
doi:10.1371/journal.pone.0049088.g001
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Accelerometer, EEG and EMG power spectra were first
normalised to the total power in that signal across all frequencies.
For acceleration, the normalisation used the total power in the first
recording of that day, allowing overall changes in tremor power to
be measured. For EEG and EMG, each spectrum was normalised
to its own total power, revealing the magnitude of spectral peaks
relative to the total. The spectra were then averaged across eight
subjects for EEG or acceleration, and across eight subjects and five
muscles for EMG. Coherence spectra were similarly averaged
across subjects and muscles; significance limits for the averaged
coherence were calculated according to the method described in
Evans and Baker [35] and Baker et al [8].
Power was summed across a frequency band of interest (6.2–
11.9 Hz for tremor; 15.3–32.2 Hz for beta-band oscillations)
within a single subject. Changes of power before and after
substance administration in these frequency bands were then
assessed using paired t-tests (P,0.05). For propranolol, we needed
to test not only whether propranolol produced a change, but
whether this change was significantly different from that produced
by placebo. Accordingly, the change in power in the relevant band
was found for each subject; these changes were compared between
placebo and propranolol (paired t-test, P,0.05).
For corticomuscular coherence, coherence was averaged across
muscles and across bins within the 15.3–32.2 Hz band for each
subject. The significance of the changes in coherence before and
after substance administration was determined by finding
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Where L is the number of disjoint sections used to calculate the
coherence, and CAftern,m(f) and C
Before
n,m(f) are the coherence
calculated at frequency bin f for subject n, muscle m before and
after substance administration. Z is computed from a sum over all
available Ns subjects, Nf frequencies (Nf = f22f1+1) and 5 muscles.
On the null hypothesis that coherence is the same before and after
substance administration, Z will be normally distributed with zero
mean and unit variance [21,30]. The significance of changes in
coherence was thus determined with reference to values of the
standard normal probability distribution.
In experiments investigating the effects of propranolol, it was
necessary to compare the changes caused by propranolol with
those seen following placebo. To achieve this, we therefore
calculated:
DZ~
1ffiffiffi
2
p ZPr opranolol{ZPlacebo
  ð2Þ
The normalisation by 1/!2 once again ensured that, on the null
hypothesis that the substances cause equal changes in coherence,
DZ will be normally distributed with zero mean and unit variance.
We determined the effect of a drug or placebo on the coherence
phase as follows. Firstly, frequency bins in the beta-band region
(15.3–32.2 Hz) for each muscle were identified which had
significant coherence both before and after substance administra-
tion. The coherence phase was measured for those bins, and the
difference in phase determined between the ‘before’ and ‘after’
conditions. The circular average of this difference was computed
[36]. We then randomly shuffled the individual paired phase
measurements, reallocating each member of a pair to the ‘before’
or ‘after’ categories; the circular average of the phase differences
was recalculated. The shuffling procedure was repeated 105 times,
allowing estimation of the distribution of the circular mean phase
difference, on the null hypothesis that there was no change before
and after substance administration. If the absolute value of the
circular average phase difference from the actual experimental
data was larger than n of the absolute values of the circular average
phase differences determined from the shuffled data, this yielded
an approximate Monte Carlo significance level of P,n/105.
Results
Figure 2 illustrates the results obtained from a single subject in
each experimental protocol tested. Figures 2A–C show the effect of
the different substances administered on physiological tremor,
measured from the acceleration power spectrum during finger
extension. In this subject, two peaks were visible in the tremor
spectra, around 8 Hz and around 20 Hz; the ,10 Hz region
usually associated with physiological tremor is marked with yellow
shading. Each panel of Fig. 2A–C relates to measurements made
on a different day; it is notable that there was high day-to-day
variability in the baseline tremor levels (compare Fig. 2C with
2A&B). There was little change in tremor following the placebo
(Fig. 2A), but a substantial reduction after propranolol (Fig. 2B) in
this subject. By contrast, salbutamol dramatically increased tremor
(Fig. 2C).
The remaining panels of Fig. 2 show results from the auxotonic
precision grip task, which was used to examine beta-band
oscillations in the motor system. Accordingly, the yellow shading
in these plots highlights the 15.3–32.2 Hz band, which encom-
passed the beta peaks. In this subject, there was a small increase in
the size of the power spectral peak at these frequencies in the
EMG following both placebo and propranolol (Fig. 2DE); this is
probably attributable to the time of day of the recordings, as the
two datasets were gathered four hours apart to allow time for
absorption of the orally administered substance. By contrast,
salbutamol appeared to have little effect on the beta band peak in
the EMG (Fig. 2F). The placebo recordings in this subject showed
a non-specific rise in EEG power across many frequencies
(Fig. 2G), but neither propranolol nor salbutamol seemed to affect
the beta-band EEG peak (Fig. 2HI).
In the initial recordings for placebo and propranolol adminis-
tration (Fig. 2JK), this subject showed weak beta-band cortico-
muscular coherence which barely rose above the significance level
(dashed lines). In both cases, the coherence peak was enhanced in
the second recording of the day. The control recording for
salbutamol showed clearer coherence (Fig. 2L), but this did not
change consistently following salbutamol inhalation. The high
day-to-day variability in baseline measures is again of note; we
have previously reported fluctuations in corticomuscular coher-
ence from single subjects both diurnally [22] and over longer
timescales [11]. Diurnal changes in coherence probably explain
the apparent effect of placebo in Fig. 2J: we have previously shown
that coherence increases in measurements made later in the day
[22].
Figure 3 shows population data on the effects of the two drugs
tested on physiological tremor. Figure 3AB plots the tremor power
spectra, averaged across all eight subjects. There appear to be
some changes in the peak around 10 Hz, with an increase in the
tremor following placebo, but a reduction following propranolol.
Figure 3C shows how the average power over the tremor band
(6.2–11.9 Hz) changed in individual subjects. Although there was
a trend for increased tremor with placebo, and decreased tremor
with propranolol, these changes were not significant. Figure 3D
Beta-Adrenergic Effects on EEG-EMG Coherence
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Figure 2. Single Subject Data. Each column of this figure refers to the effects of a different substance: placebo (A,D,G,J), propranolol (B,E,H,K) and
salbutamol (C,F,I,L). A–C, effect on postural tremor during an index finger extension task. Traces show the power spectrum of the finger acceleration,
before and after substance ingestion. Yellow shaded region corresponds to the band of physiological tremor (6.2–11.9 Hz). D–F, effect on EMG
power. G–I, effect on EEG power. J–L, effect on corticomuscular coherence. In (D–L), all measurements were made during the second hold phase of a
hold-ramp-hold auxotonic precision grip task (see Methods). Yellow shaded region marks the 15.3–32.2 Hz band of beta oscillations. EMG power
spectra (D–F) and corticomuscular coherence (J–L) have been averaged over all five muscles recorded. In (J–L), horizontal dashed lines indicate the
significance level for the averaged coherence.
doi:10.1371/journal.pone.0049088.g002
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presents individual data on the change in tremor power following
each substance. The difference in tremor was smaller for
propranolol than for placebo in 7/8 subjects. This change was
significantly different: propranolol reduced tremor compared with
placebo (P,0.05, paired t-test and also binomial test).
Figure 3E shows averaged power spectra of finger acceleration
before and after the inhalation of salbutamol. As with the single
subject illustrated in Fig. 2C, salbutamol markedly increased the
average tremor peak. The changes seen in individual subjects are
presented in Fig. 3F; salbutamol significantly increased tremor
power across the subject population.
These results confirm that – at the doses used here –
propranolol reduces, but salbutamol increases, physiological
tremor, which is in accord with previous work [24] and also
common clinical experience.
Figure 4 presents the effects of propranolol on oscillations
during the second hold phase of the precision grip task. Figure 4AB
shows the EMG power spectra, averaged over all eight subjects
and five muscles. In both cases, the recordings made later in the
day showed a more pronounced beta-band spectral peak.
Figure 4C shows individual measures of beta-band power; there
were significant increases following both propranolol and placebo
administration. However, a comparison of the changes in power
(Fig. 4D) revealed no significant difference between the effects of
propranolol and placebo.
Using the same format, Fig. 4E–H presents the changes in EEG
power following placebo and propranolol administration. In both
cases there was a slight increase in the beta-band power peak,
which became significant for propranolol (Fig. 4G). However, as
for the EMG power, there were no significant differences between
the effects of propranolol and placebo.
For both EEG and EMG power we normalised values in a given
frequency bin relative to the total power, summed across all
frequencies. We also verified that there were no significant changes
in the total power, for any of the comparisons described by
Fig. 4CDGH.
Finally, Fig. 4I–L shows how corticomuscular coherence altered
following ingestion of these substances. There was a very small
increase in coherence following placebo, but a more pronounced
increase following propranolol (Fig. 4IJ); both of these effects
reached significance (Fig. 4K). Propranolol increased beta-band
corticomuscular coherence more than placebo (Fig. 4L) in 7/8
subjects, significantly so (using an individual difference of
coherence test) in 3 subjects. At a population level, the increase
following propranolol was significantly greater than after placebo
using the difference of coherence test described in Methods
(P,0.001), and also on a binomial test (P,0.05).
The results from the precision grip task following salbutamol
inhalation are shown in Fig. 5. There were small or negligible
changes in the averaged beta band power spectral peaks in both
EMG and EEG signals (Fig. 5AC); these were not consistent across
subjects (Fig. 5BD) and not significant. Similarly, the averaged
corticomuscular coherence decreased slightly (Fig. 5E), but this
was not significant (Fig. 5F).
Experiments with propranolol used a double-blind placebo
controlled design, as the long absorption time consequent on oral
administration made it necessary to control for an effect of the
time of day when recordings were made. By contrast, the rapid
action of the salbutamol delivered by inhalation meant that control
and drug recordings were made with only brief temporal
separation. We thus chose not to make the comparison with
placebo in this case. Additionally, the effects of salbutamol on
heart rate and tremor were clearly apparent to the subjects, so that
a double-blinded study would have been impossible. Several pieces
of evidence indicated that the changes we saw following
salbutamol were genuine effects of the drug, rather than reflecting
progressive changes in the successive recordings. For corticomus-
cular coherence, Pohja et al [37] previously showed that successive
measurements were highly repeatable. We also tested directly for
reproducibility, by dividing each dataset recorded before salbuta-
mol administration into two. The results from this analysis are
shown in Fig. 6, for both tremor (Fig. 6AB) and corticomuscular
coherence (Fig. 6CD). In neither case were there significant
differences between measures made from the first versus last half of
the recorded data (P.0.05). There may have been some weak
trend towards reduced tremor in the later part of the recording
(P= 0.14; Fig. 6B); however, even if this effect were genuine, it
would be in the opposite direction to that seen following
salbutamol administration (Fig. 3EF).
Figure 3. Effects on Resting Tremor. All measurements in this
figure were taken during index finger extension. A, B, changes in finger
acceleration power spectra, averaged across all eight subjects, before
and after administration of placebo (A) and propranolol (B). C, total
acceleration power over the 6.2–11.9 Hz range (yellow shading in A,B)
before and after substance administration. Each point shows data from
one subject; lines link data from the same subject. Data points are
colour coded to match the colours used in (A,B). There was no
significant change in tremor power after either placebo or propranolol.
D, changes in tremor power after administration of placebo or
propranolol. Each point shows the difference between the ‘after’ and
‘before’ points from the corresponding subject shown in (C).
Propranolol reduced tremor power significantly compared to placebo
(P,0.05). E, changes in finger acceleration power spectra, averaged
across all eight subjects, before and after administration of salbutamol.
F, total acceleration power over the 6.2–11.9 Hz range (yellow shading
in E) before and after salbutamol administration. Tremor power was
significantly increased after salbutamol (P,0.05).
doi:10.1371/journal.pone.0049088.g003
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Phase analysis provides important clues as to the underlying
network and the likely explanation for changes in corticomuscular
coherence. In order to investigate phase changes, in each EMG
and each subject we found the frequency bins in the 15.3–32.2 Hz
range which showed significant coherence both before and after
substance administration. The phase of the coherence following
administration of a substance was then plotted against the phase
measured in the control experiment. Figure 7 shows the results of
such an analysis, with points overlain from all EMGs and subjects.
Results from placebo, propranolol, and salbutamol respectively are
shown in Fig. 7A, B and C. Significant changes in phase were seen
in the salbutamol dataset (circular mean phases before and after
substance administration: 1.63 vs 1.51 rad, P<0.026, Monte Carlo
test). Similarly significant differences were seen when the two
outlying points with negative phase before drug administration
were excluded from the analysis (P<0.017, Monte Carlo test).
There were no significant changes in phase for either propranolol
or placebo (both P.0.05).
Discussion
Differential Effects on Tremor and Corticomuscular
Coherence
Surprisingly, the drugs tested in this study had different effects
on,20 Hz corticomuscular coherence and,10 Hz tremor (Fig. 3
versus Figs. 4&5). For propranolol, the effects were reciprocal
Tremor showed a weak but non-significant trend to increase at the
later time of day of the second recordings with placebo (Fig. 3AC);
by contrast, when propranolol was given there was a non-
significant trend in the reverse direction (Fig. 3BD). Comparison of
Figure 4. Effects of Propranolol on Beta-band Oscillations during the Auxotonic Precision Grip Task. A,B, EMG power spectra, averaged
across all eight subjects and five muscles, before and after administration of placebo (A) and propranolol (B). C, total EMG power in the 15.3–32.2 Hz
beta band (shaded yellow in A,B), plotted for single subjects before and after placebo and propranolol. Both substances significantly increased EMG
beta power. D, changes in EMG power in the 15.3–32.2 Hz band produced by placebo and propranolol. Each point is the difference of the ‘after’ and
‘before’ points from the corresponding subject in (C). There was no significant difference in the change in beta-band power between placebo and
propranolol. E–H, similar display as (A–D), but for EEG power. Propranolol significantly increased EEG power in the beta band, but there was no
significant difference between the changes seen after placebo and propranolol. I–L, similar display as (A–D), but for corticomuscular coherence
(averaged over all five available muscles). Dashed horizontal lines in (I,J) mark the significance level for the averaged coherence (P,0.05). Coherence
was significantly increased after both placebo and propranolol (K), but the change in coherence was significantly greater for propranolol than for
placebo (L).
doi:10.1371/journal.pone.0049088.g004
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these two effects revealed a significant difference, indicating that
propranolol reduced tremor compared with placebo (Fig. 3D). By
contrast, propranolol elevated corticomuscular coherence (Fig. 4L).
Such results are reminiscent of findings from our computational
model of the effect of recurrent inhibition [29]. In this model,
,10 Hz frequency components of the motor cortical input to
motoneurones are removed by Renshaw cells, behaving as phase
inverting filters, and thus ,10 Hz tremor is reduced. By
manipulating the strength of Renshaw cell recurrent inhibition,
this model showed a reciprocal relationship between ,10 Hz
tremor and beta-band corticomuscular coherence (see Fig. 4 in
[29]). Although the largest effect on corticomuscular coherence in
the model was at 30 Hz, coherence in the entire band from 20–
40 Hz was raised by increasing Renshaw cell feedback.
Whereas salbutamol clearly increased ,10 Hz tremor
(Fig. 3EF), there was no significant change in corticomuscular
coherence across the subject population (Fig. 5F). It is not clear
why salbutamol and propranolol failed to exert reciprocal effects
on the corticomuscular coherence. This may simply be due to the
low doses used, which were chosen to minimise the chances of side
effects in our healthy volunteer subjects, or to b1-receptor or b3-
receptor mediated effects (salbutamol is a b2-agonist, whereas
propranolol is a non-specific b-receptor antagonist).
Location of peripheral and central b-Adrenergic
Receptors Mediating Effects
Whilst part of the action of the non-specific beta-blocker
propranolol on physiological tremor could be via a peripheral site
[23,24,28], it seems likely, in the light of our results, that there is
also a central action [38]. In support of this hypothesis,
propranolol, which is lipophilic, is significantly more effective at
both reducing tremor [24], and penetrating the blood brain
barrier [39] than the hydrophilic atenolol. Whether the central
effects of propranolol are mediated via one specific class of beta-
adrenergic receptor or a combination is unclear. All subtypes of
beta-adrenergic receptors are widely distributed throughout the
central nervous system. Immunohistochemistry has identified b1-
adrenergic receptors in the amygdala, hippocampus, hypothala-
mus, cerebellum, midbrain reticular nuclei, inferior olive and
striatum [40] and b2-adrenergic receptors in the locus coeruleus [42]
and soma and proximal dendrites of thalamo-cortical neurones
[41]. In situ hybridisation has further revealed b2-adrenergic
receptors in the thalamic intralaminar nuclei, cerebellar cortex
[42] and superficial dorsal horn of spinal cord [43]. b3-adrenergic
receptor mRNA has been detected in homogenates of frontal,
temporal and parietal cortex, hippocampus, striatum and
midbrain by reverse transcription/polymerase chain reaction
methods [44,45].
Figure 5. Effects of Salbutamol on Beta-band Oscillations
during the Auxotonic Precision Grip Task. A, EMG power
spectrum, averaged over all five muscles and eight subjects, before
and after administration of salbutamol. B, total power in the 15.3–
32.2 Hz band (shaded yellow in A) before and after salbutamol
inhalation. Each point gives data from a single subject. C,D, as (A,B),
but for EEG power. E,F, as (A,B), but for corticomuscular coherence.
Dashed horizontal line in (E) marks the significance limit for the
coherence (P,0.05). None of the measures displayed in (B,D,F)
significantly changed after salbutamol administration (P.0.05).
doi:10.1371/journal.pone.0049088.g005
Figure 6. Reproducibility of Tremor and Corticomuscular
Coherence. A, finger acceleration power spectra, measured prior to
salbutamol administration, averaged across all eight subjects. The
available recording from each subject was divided in half, and each half
analysed separately. B, total acceleration power over the 6.2–11.9 Hz
range (yellow shading in A) in each half of the recording. Each point
shows data from one subject; lines link data from the same subject.
Data points are colour coded to match the colours used in (A). C,
corticomuscular coherence, averaged over all five muscles and eight
subjects, measured from the first and last half of the available recording
in each subject during performance of the auxotonic precision grip task.
D, single subject data for the average coherence in the 15.3–32.2 Hz
band (yellow shading in C), using the same format at (B). There was no
significant change in either tremor or coherence between the first and
last half of the recorded datasets (P.0.05).
doi:10.1371/journal.pone.0049088.g006
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Of the likely candidate motor areas implicated, it is unlikely that
b-adrenergic effects on corticomuscular coherence are explained
by actions on the cerebellum. It is known that ,20 Hz oscillations
are propagated around a loop from motor cortex to cerebellum
and back [43]. However, changing the properties of this loop
should change only the nature of oscillations observed in the
cortex, and not alter the coupling between cortex and periphery.
Given our previous results from computational modelling, we
speculate that propranolol acts centrally via Renshaw cells,
producing a reciprocal modulation of ,10 Hz tremor and 20–
30 Hz corticomuscular coherence. Because Renshaw cells them-
selves are not known to have b-receptors, these effects would have
to be mediated indirectly via inputs from neurons expressing b-
adrenergic receptors, including those within the locus coeruleus (LC)
and spinal dorsal horn. Interestingly, in the cat, Renshaw cells are
in receipt of direct adrenergic reticulospinal inputs from LC,
which when activated reduce recurrent inhibition [43]. Moreover,
the b3-agonist (SR58611A) increases the firing rate of noradren-
ergic neurons in the locus coeruleus [44].
In contrast to propranolol, the striking lack of any effect of the
b2-agoinst salbutamol upon coherence suggests that its predom-
inant mode of action is via peripheral receptors. b2-adrenergic
receptors are certainly found in abundance in extrafusal muscle
where they mediate diverse functions including: metabolic
regulation [46]; myocyte hypertrophy [47]; and repair [48].
These actions occur over a protracted time course and are
therefore unlikely to be responsible for salbutamol’s rapid effects
on tremor. Faster processes are also mediated via b2-receptors.
They decrease muscle excitability by closing inward rectifying
potassium channels, opening calcium-activated potassium chan-
nels [49] and blocking sodium currents [50]. In addition, because
sympathetic activity produces rapid changes in blood flow to
skeletal muscle, it has been argued that ischaemia (or its
consequences e.g. hyperkalaemia) might affect tremor by changing
the biophysical properties of muscle [28].
Network re-organization
Although the literature is conflicting [4,51–54], the phase of
corticomuscular coherence often does not agree with simple
efferent propagation of oscillations from motor cortex to the
periphery [7,11,19]. Rather, coherence phase probably reflects a
complex interplay of feedforward and feedback pathways. In the
present work, we showed that salbutamol produced a small but
significant reduction in the coherence phase (Fig. 6). Although
salbutamol did not change the magnitude of coherence, the
reduction in phase might reflect a slight shift in the balance
between feedforward and feedback pathways contributing to the
coherence [11]. This could occur either by central actions of the
drug, or via its previously reported peripheral actions. Beta-
agonists are likely to increase the sensitivity of muscle spindles
[24], whose afferents are known to encode beta-band oscillations
[8].
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